Boothbay Fund Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
Boothbay Fund Management's LCTX Position: Q3 2026 in Review
Boothbay Fund Management held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 10,000 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1953.
Boothbay Fund Management first reported a position in LCTX in Q4 2021 and has held it in 8 quarters since. The position peaked at $112K in Q1 2023. 143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- Boothbay Fund Management held 10,000 shares of Lineage Cell Therapeutics worth $9.6K as of Q3 2026.
- Boothbay Fund Management left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q3 2026, its #1953 holding.
- Boothbay Fund Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and has held it in 8 quarters since.
- Boothbay Fund Management's Lineage Cell Therapeutics position peaked at $112K in Q1 2023.
- 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.